These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 17392628)

  • 1. Natalizumab: overview of its pharmacology and safety.
    Baker DE
    Rev Gastroenterol Disord; 2007; 7(1):38-46. PubMed ID: 17392628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH; Bressler B
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody.
    Drugs R D; 2004; 5(2):102-7. PubMed ID: 15293871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab for the treatment of Crohn's disease.
    Bickston SJ; Muniyappa K
    Expert Rev Clin Immunol; 2010 Jul; 6(4):513-9. PubMed ID: 20594122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
    Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
    Foley J
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S178-83. PubMed ID: 20615054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab induction and maintenance therapy for Crohn's disease.
    Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
    N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.
    Sands BE; Kozarek R; Spainhour J; Barish CF; Becker S; Goldberg L; Katz S; Goldblum R; Harrigan R; Hilton D; Hanauer SB
    Inflamm Bowel Dis; 2007 Jan; 13(1):2-11. PubMed ID: 17206633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab.
    Ghosh S
    Expert Opin Biol Ther; 2003 Sep; 3(6):995-1000. PubMed ID: 12943458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab update.
    Sweet BV
    Am J Health Syst Pharm; 2007 Apr; 64(7):705-16. PubMed ID: 17384355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
    Keeley KA; Rivey MP; Allington DR
    Ann Pharmacother; 2005 Nov; 39(11):1833-43. PubMed ID: 16219898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Tysabri survived.
    Huggett B
    Nat Biotechnol; 2009 Nov; 27(11):986. PubMed ID: 19898447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcoidosis complicating treatment with natalizumab for Crohn's disease.
    Parisinos CA; Lees CW; Wallace WA; Satsangi J
    Thorax; 2011 Dec; 66(12):1109-10. PubMed ID: 21233484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatalities in natalizumab treatment--a 'no go' for leukocyte recirculation approaches?
    Li YY; Perez HD; Zollner TM
    Expert Opin Ther Targets; 2006 Aug; 10(4):489-99. PubMed ID: 16848686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab (Tysabri) for Crohn's disease.
    Med Lett Drugs Ther; 2008 May; 50(1285):34-6. PubMed ID: 18458669
    [No Abstract]   [Full Text] [Related]  

  • 19. Natalizumab for active Crohn's disease.
    Ghosh S; Goldin E; Gordon FH; Malchow HA; Rask-Madsen J; Rutgeerts P; Vyhnálek P; Zádorová Z; Palmer T; Donoghue S;
    N Engl J Med; 2003 Jan; 348(1):24-32. PubMed ID: 12510039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
    Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
    J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.